---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Cost assumptions"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Cost assumptions. Topics: ICER drug prices: baxdrostat, lorundrostat placeholder, and generic comparators; ICER dosing regimens costed; ICER health state costs; Lorundrostat price: manufacturer statements; 4 further topics. 8 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics/cost-assumptions"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Cost assumptions

<a id="heading-4.2.4"></a>

## 4.2.4 Cost Assumptions

<a id="topic-4.2.4-1"></a>

### ICER drug prices: baxdrostat, lorundrostat placeholder, and generic comparators

> “For baxdrostat, we used the wholesale acquisition cost (WAC) price from RedBook ($900 for 30 tablets). Given that baxdrostat was recently launched, and no information is available to inform a discount from WAC, the WAC price was used as the net price. For lorundrostat, we used the baxdrostat WAC price as a placeholder price. For comparator drugs (spironolactone, eplerenone, and amiloride) we obtained net pricing estimates from Redbook based on the median cost (WAC) across all generic versions.”
> “We used the net prices and the threshold prices (at $50,000, $100,000, $150,000, and $200,000 per evLY gained) for baxdrostat and lorundrostat when compared to each comparator to estimate the percentage of the eligible population that could be treated before reaching the ICER potential budget impact threshold of $821 million.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Drug | WAC per dose | Net price per dose | Net price per year |
| --- | --- | --- | --- |
| Spironolactone (25 mg) | “$0.117” | “$0.117” | “$43” |
| Spironolactone (100 mg) | “$0.4683” | “$0.4683” | “$171” |
| Eplerenone (50 mg) | “$1.3997” | “$1.3997” | “$511” |
| Eplerenone (100 mg) | “$2.793” | “$2.793” | “$1,022” |
| Amiloride (5 mg) | “$0.5627” | “$0.5627” | “$206” |
| Amiloride (10 mg) | “$1.1253” | “$1.1253” | “$411” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Intervention (dosage) | WAC per dose | Net annual cost | Source |
| --- | --- | --- | --- |
| Lorundrostat (50 mg/day) | “$30” | “$10,950” | “Placeholder” |
| Baxdrostat (2 mg/day) | “$30” | “$10,950” | “Redbook” |
| Spironolactone (25–100 mg/day) | “$0.12–$0.47” | “$43–$171” | “Redbook” |
| Eplerenone (50–100 mg/day) | “$1.40–$2.79” | “$511–$1,022” | “Redbook” |
| Amiloride (5–10 mg/day) | “$0.56–$1.13” | “$206–$411” | “Redbook” |

Source: [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf)

<a id="topic-4.2.4-2"></a>

### ICER dosing regimens costed

| Drug | Quoted dosing |
| --- | --- |
| Lorundrostat | “50 mg once daily” |
| Baxdrostat | “1 or 2 mg once daily” |
| Spironolactone | “25-100 mg once daily” |
| Eplerenone | “50 mg once to twice daily” |
| Amiloride | “5-10 mg once daily” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.4-3"></a>

### ICER health state costs

> “Non-drug health care costs were applied as health state costs reflecting the direct medical care associated with each health state in the model.”
> “Included one-time costs of hyperkalemia monitoring ($11) for all five treatments.”

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

| Health state | Annual cost (2025 US dollars) |
| --- | --- |
| Hypertension (annual) | “$3,211” |
| Stroke (acute and annual) | “$20,442 / $20,697” |
| Myocardial infarction (acute and annual) | “$25,832 / $17,106” |
| Coronary heart disease (annual) | “$13,798” |
| Heart failure (index hospitalization and annual) | “$16,671 / $33,890” |
| End-stage kidney disease (annual) | “$108,953” |

Source: [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)

<a id="topic-4.2.4-4"></a>

### Lorundrostat price: manufacturer statements

> “We have talked in the past, Annabel, that as a guidance or a frame for pricing, we have always directed to probably more of an SGLT2-branded price point, Entresto price point, broadly at a WAC, but have not guided as it relates to rebates.”
> “I think we continue to feel very strong about the value proposition of lorundrostat, the need specifically in the resistant hypertension population, and so we believe that both the combination of appropriate price and rebate is going to create that access.”

Source: [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)

<a id="topic-4.2.4-5"></a>

### Comparator acquisition cost: National Average Drug Acquisition Cost, spironolactone 25 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “SPIRONOLACTONE 25 MG TABLET” |
| NADAC per unit | “0.04218” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, spironolactone 25 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=53489014310&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.4-6"></a>

### Comparator acquisition cost: National Average Drug Acquisition Cost, eplerenone 50 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “EPLERENONE 50 MG TABLET” |
| NADAC per unit | “0.47438” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, eplerenone 50 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=31722005030&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.4-7"></a>

### Comparator acquisition cost: National Average Drug Acquisition Cost, amiloride 5 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “AMILORIDE HCL 5 MG TABLET” |
| NADAC per unit | “0.20688” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, amiloride 5 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=42794000502&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

<a id="topic-4.2.4-8"></a>

### Comparator acquisition cost: National Average Drug Acquisition Cost, baxdrostat 2 mg

| Field | Quoted record |
| --- | --- |
| NDC description | “BAXFENDY 2 MG TABLET” |
| NADAC per unit | “28.78424” |
| Effective date | “2026-11-18” |

Source: [CMS NADAC, BAXFENDY 2 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=00310600230&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
